ALLG MM16: This phase II trial is assessing carfilzomib (an anti-cancer drug) in patients with Multiple Myeloma who suffer from renal damagePhase II study assessing the effect of carfilzomib treatment on early free light chain kinetics in myeloma patients with renal impairmen

Exclusion

Presence of any of the following criteria will exclude the subject from enrolment in the study.

Patients who have had myocardial infarction within 6 months prior to enrolment, or NYHA (New York Hospital Association) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia or active conduction system abnormalities at any time.

Other uncontrolled intercurrent illness including, but not limited to, severe active infection, or psychiatric illness/social situations that would limit compliance with study requirements

Evidence of infection, dehydration or hypercalcaemia as the cause of acute kidney injury that has not been corrected.

Patients on dialysis at Screening.

Patients with known amyloidosis.

Patients with myelodysplastic syndrome.

Known history of allergy to Captisol (a cyclodextrin derivative used to solubilise carfilzomib)

Patients with contraindication to dexamethasone.

Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to antiviral drugs, or intolerance to hydration due to pre-existing pulmonary or cardiac impairment.

Women who are pregnant or lactating. Females of child-bearing potential must have a negative urine pregnancy test at Screening.

Known Hepatitis B, Hepatitis C, HIV infection, other immunosuppressive therapy including dexamethasone or autoimmune disease

Prior diagnosis of cancer that was:
more than 5 years prior to current diagnosis with subsequent evidence of disease recurrence or clinical expectation of recurrence is greater than 10%.
within 5 years of current diagnosis with the exception of successfully treated basal cell or squamous cell skin carcinoma or carcinoma in situ of the cervix.

Participation in other therapeutic studies in the last 60 days except for studies with a non-medical intervention. Documented evidence of receiving placebo will be required.

Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. This condition must be discussed with the patient prior to signing consent and registration in the trial.